Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.

Moreover, all 12 showed evidence that the islet cells had grafted and were ... a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from ...

Along with VX-880, it is also working on encapsulated islet cells as a treatment for T1D, although that programme remains in preclinical development. Encapsulation could mean doing away with the ...

stem cell-derived beta islet cell precursors to address type 1 diabetes without the need for chronic immunosuppression, including both encapsulated and unencapsulated approaches. The stock ...

More recent advances in islet transplantation derive from islet encapsulation devices, biomaterial platforms releasing immunomodulatory compounds or surface-modified with immune regulating ligands, ...